<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: We assessed the incidence of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, defined as serum total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> &gt;/=15 mg/dL (256 micromol/L), in a cohort of Sephardic Jewish female neonates at risk for <z:chebi fb="105" ids="17234">glucose</z:chebi>-6-phosphate dehydrogenase (G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) deficiency with especial emphasis on the heterozygotes </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the roles of <z:mp ids='MP_0010163'>hemolysis</z:mp> by blood carboxyhemoglobin (COHb) determinations and of the variant promoter of the gene for the <z:chebi fb="0" ids="16990">bilirubin</z:chebi>-conjugating enzyme <z:chebi fb="0" ids="16704">uridine</z:chebi> 5'-<z:chebi fb="2" ids="18361">diphosphate</z:chebi> glucuronosyltransferase 1 (UGT1A1) seen in <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> in the pathogenesis of the <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Consecutively born, healthy, term, female neonates were screened for <z:e sem="disease" ids="C0017758" disease_type="Disease or Syndrome" abbrv="">G-6-PD deficiency</z:e> and observed clinically with serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> evaluations as indicated for <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>On day 3, blood was sampled for COHb, total <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> (tHb), and a mandatory serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> determination </plain></SENT>
<SENT sid="4" pm="."><plain>COHb, determined by gas chromatography, was expressed as percentage of tHb and corrected for inspired <z:chebi fb="168" ids="17245">carbon monoxide</z:chebi> (COHbc) </plain></SENT>
<SENT sid="5" pm="."><plain>DNA was analyzed for the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> Mediterranean563T mutation and for the variant UGT1A1 gene </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The cohort included 54 G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient heterozygotes, 19 deficient homozygotes, and 112 <z:mpath ids='MPATH_458'>normal</z:mpath> homozygotes </plain></SENT>
<SENT sid="7" pm="."><plain>More heterozygotes (12/54, 22%; relative risk: 2.26; 95% CI: 1.07-4.80) and deficient homozygotes (5/19, 26.3%; relative risk: 2.68; 95% CI: 1.05-6.90) developed <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, than did <z:mpath ids='MPATH_458'>normal</z:mpath> homozygotes (11/112, 9.8%) </plain></SENT>
<SENT sid="8" pm="."><plain>Third-day serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> values that were obtained from 144 neonates were significantly higher in both heterozygotes (11.2 +/- 3 </plain></SENT>
<SENT sid="9" pm="."><plain>7 mg/dL [192 +/- 64 micromol/L]) and G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient homozygotes (12.0 +/- 3.0 mg/dL [206 +/- 52 micromol/L]) than in the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> <z:mpath ids='MPATH_458'>normal</z:mpath> homozygotes (9.4 +/- 3.4 mg/dL [160 +/- 58 micromol/L) </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, COHbc values were higher only in G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient homozygotes (0.74% +/- 0.14%) and not in heterozygotes (0.69% +/- 0 </plain></SENT>
<SENT sid="11" pm="."><plain>19%, not statistically significant), compared with control values (0 </plain></SENT>
<SENT sid="12" pm="."><plain>63% +/- 0.19%) </plain></SENT>
<SENT sid="13" pm="."><plain>High COHbc values were not a prerequisite for the development of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in any of the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> genotypes </plain></SENT>
<SENT sid="14" pm="."><plain>A greater incidence of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> was found among the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient heterozygotes, who also had the variant UGT1A1 gene, in both heterozygous (6/20, 30%) and homozygous (4/8, 50%) forms, than was found in their counterparts with the <z:mpath ids='MPATH_458'>normal</z:mpath> UGT1A1 gene (2/26, 7.7%) </plain></SENT>
<SENT sid="15" pm="."><plain>This effect was not seen in the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> <z:mpath ids='MPATH_458'>normal</z:mpath> homozygote group </plain></SENT>
<SENT sid="16" pm="."><plain>A color reduction screening test for <z:e sem="disease" ids="C0017758" disease_type="Disease or Syndrome" abbrv="">G-6-PD deficiency</z:e> identified only 20.4% (11/54) of the heterozygotes </plain></SENT>
<SENT sid="17" pm="."><plain>CONCLUSIONS: We showed that G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient heterozygotes, categorically defined by DNA analysis, are at increased risk for <z:hpo ids='HP_0003265'>neonatal hyperbilirubinemia</z:hpo> </plain></SENT>
<SENT sid="18" pm="."><plain>The screening test that was used was unable to detect most heterozygotes </plain></SENT>
<SENT sid="19" pm="."><plain><z:hpo ids='HP_0003573'>Increased bilirubin</z:hpo> production was not crucial to the development of <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo>, but presence of the variant UGT1A1 gene did confer increased risk </plain></SENT>
</text></document>